Overview

Latest Presentation

Read about how Zymeworks is growing into a major global competitor.

Latest Conference Call

We are committed to high standards of corporate governance and business integrity.

Company Profile

Zymeworks is an innovative, clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. Our suite of complementary therapeutic platforms and our fully-integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly-differentiated product candidates. These capabilities have resulted in multiple wholly-owned product candidates with the potential to drive superior outcomes in large underserved and unaddressed patient populations.

Our lead product candidate, ZW25, is a novel bispecific (dual-targeting) antibody currently being evaluated in a Phase 2 clinical trial, targeting two distinct domains of the human epidermal growth factor receptor 2, or HER2, a protein that promotes the growth of cancer cells. Our second product candidate, ZW49, a novel bispecific antibody drug conjugate (ADC) has entered into a Phase 1 clinical trial.

In addition to our wholly-owned pipeline, two of our therapeutic platforms have been further leveraged through multiple revenue-generating strategic partnerships with the following global pharmaceutical companies: Merck, Eli Lilly, Celgene, GSK, Daiichi Sankyo, Johnson & Johnson, LEO Pharma, and BeiGene.